Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1888
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) ; volume:19 ; number:3 ; day:29 ; month:3 ; year:2018 ; pages:457 ; date:6.2018
American journal of clinical dermatology ; 19, Heft 3 (29.3.2018), 457, 6.2018
- Creator
-
Blauvelt, Andrew
- Contributor
-
Papp, Kim A.
Griffiths, Christopher E. M.
Puig, Luis
Weisman, Jamie
Dutronc, Yves
Kerr, Lisa Farmer
Ilo, Dapo
Mallbris, Lotus
Augustin, Matthias
SpringerLink (Online service)
- DOI
-
10.1007/s40257-018-0353-x
- URN
-
urn:nbn:de:101:1-2018071514040796024126
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Blauvelt, Andrew
- Papp, Kim A.
- Griffiths, Christopher E. M.
- Puig, Luis
- Weisman, Jamie
- Dutronc, Yves
- Kerr, Lisa Farmer
- Ilo, Dapo
- Mallbris, Lotus
- Augustin, Matthias
- SpringerLink (Online service)
Other Objects (12)
Correction to: GP2015: An Etanercept Biosimilar
Tracing lineages to uncover neuronal identity
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
Detangling PPI networks to uncover functionally meaningful clusters
From Melville to Saunders: Using Liminality to Uncover US-American Racial Fantasies
Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J)
Summary of worldwide pediatric malignancies reported after exposure to etanercept
Using forecasts to uncover the loss function of FOMC members
Dauer as a model to uncover mechanisms of tissue maintenance
Correction to: GP2015: An Etanercept Biosimilar
Tracing lineages to uncover neuronal identity
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
Detangling PPI networks to uncover functionally meaningful clusters
From Melville to Saunders: Using Liminality to Uncover US-American Racial Fantasies
Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J)
Summary of worldwide pediatric malignancies reported after exposure to etanercept
Using forecasts to uncover the loss function of FOMC members
Dauer as a model to uncover mechanisms of tissue maintenance
Correction to: GP2015: An Etanercept Biosimilar
Tracing lineages to uncover neuronal identity
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials
Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
Detangling PPI networks to uncover functionally meaningful clusters
From Melville to Saunders: Using Liminality to Uncover US-American Racial Fantasies
Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
Relationship Between Rapid Skin Clearance and Quality of Life Benefit: Post Hoc Analysis of Japanese Patients with Moderate-to-Severe Psoriasis Treated with Ixekizumab (UNCOVER-J)
Summary of worldwide pediatric malignancies reported after exposure to etanercept
Using forecasts to uncover the loss function of FOMC members